A new pooled analysis of the Phase 3 EINSTEIN trial program showed that Xarelto (rivaroxaban; Janssen) is as effective as the standard of care in reducing the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients with symptomatic DVT/PE. 

RELATED: Cardiovascular Disease Resource Center

Also, Xarelto was shown to reduce the incidence of major bleeding by 46%. The safety and efficacy outcomes were further consistent across the participant subgroups: fragile subjects, those with cancer, subjects with a history of recurrent VTE, and those with a large clot.

Jack E. Ansell, MD, MACP, Professor of Medicine at NYU School of Medicine, explained that the current standard of care for DVT/PE “requires a two-drug regimen: a rapidly acting, injectable anticoagulant with an oral Vitamin K antagonist, such as warfarin.” 

The EINSTEIN trial program supports that a single oral agent like Xarelto has a lower incidence of major bleeding compared to standard of care.

This pooled analysis included results from the EINSTEIN-DVT and EINSTEIN-PE studies that evaluated >8,000 patients, split between the DVT (n=3,449) and PE (n=4,833) studies. 

The analysis was pre-specified to be able to assess the overall efficacy and safety of Xarelto for the treatment of venous thromboembolism. Findings from the analysis were published in Volume 11, Issue 21 of the Thrombosis Journal.

Xarelto is an oral Factor Xa inhibitor approved for six clinical uses, including to treat DVT/PE and to reduce the risk of recurrent events.

For more information call (888) 927-3586 or visit the Thrombosis Journal website